Alkali hydrolysis of recombinant proteins allows for the rapid identification of class I MHC-restricted CTL epitopes - PubMed (original) (raw)
. 1993 Oct 15;151(8):3971-80.
Affiliations
- PMID: 7691936
Alkali hydrolysis of recombinant proteins allows for the rapid identification of class I MHC-restricted CTL epitopes
M A Gavin et al. J Immunol. 1993.
Abstract
The characterization of the epitopes recognized by CTL provides insights into the nature of protective immune responses and facilitates the development of methods to enhance immunity to human pathogens. However, no easily applicable approach for CTL epitope identification has been developed. We present a rapid and efficient method for locating CTL epitopes within a protein. The gene encoding the protein of interest is inserted into an inducible prokaryotic expression vector. Random peptides are then generated by alkali digestion of intact or lysed Escherichia coli expressing the protein and assayed for the presence of the epitope by coating target cells for a standard CTL targeting assay. A large panel of clones containing serial 3'-deletions of the gene is then generated by exonuclease III digestion, and the expressed truncated proteins are similarly analyzed for the presence of the antigenic peptide. The epitope is located by determining the deletion points of clones expressing sequential truncations and differing in Ag expression. This technique was used to identify the H-2Ld-restricted nonamer in E. coli beta-galactosidase, with residues 876-884 representing the naturally processed epitope. To test the applicability of this method to other proteins, two genes from human CMV, an often fatal pathogen in immunocompromised individuals, were screened for HLA class I-restricted epitopes. An HLA-B18-restricted epitope from the CMV major immediate-early protein was found to lie between residues 378 and 389, and an HLA-B35-restricted epitope from the CMV pp65 matrix protein was characterized as residues 123 to 131. The results demonstrate that this technique can be used to rapidly identify CTL epitopes within a chosen protein and should be useful for assaying viral isolates or neoplasms for loss of epitopes after mutation and selection by host immune responses.
Similar articles
- Identification of novel CTL epitopes of CMV-pp65 presented by a variety of HLA alleles.
Kondo E, Akatsuka Y, Kuzushima K, Tsujimura K, Asakura S, Tajima K, Kagami Y, Kodera Y, Tanimoto M, Morishima Y, Takahashi T. Kondo E, et al. Blood. 2004 Jan 15;103(2):630-8. doi: 10.1182/blood-2003-03-0824. Epub 2003 Aug 28. Blood. 2004. PMID: 12947002 - An epitope in hepatitis C virus core region recognized by cytotoxic T cells in mice and humans.
Shirai M, Okada H, Nishioka M, Akatsuka T, Wychowski C, Houghten R, Pendleton CD, Feinstone SM, Berzofsky JA. Shirai M, et al. J Virol. 1994 May;68(5):3334-42. doi: 10.1128/JVI.68.5.3334-3342.1994. J Virol. 1994. PMID: 7512163 Free PMC article. - Alternative processing pathways for MHC class I-restricted epitope presentation to CD8+ cytotoxic T lymphocytes.
Reimann J, Böhm W, Schirmbeck R. Reimann J, et al. Biol Chem Hoppe Seyler. 1994 Nov;375(11):731-6. doi: 10.1515/bchm3.1994.375.11.731. Biol Chem Hoppe Seyler. 1994. PMID: 7535058 Review.
Cited by
- Prevention of CMV/EBV reactivation by double-specific T cells in patients after allogeneic stem cell transplantation: results from the randomized phase I/IIa MULTIVIR-01 study.
Gerbitz A, Gary R, Aigner M, Moosmann A, Kremer A, Schmid C, Hirschbuehl K, Wagner E, Hauptrock B, Teschner D, Roesler W, Spriewald B, Tischer J, Moi S, Balzer H, Schaffer S, Bausenwein J, Wagner A, Schmidt F, Brestrich J, Ullrich B, Maas S, Herold S, Strobel J, Zimmermann R, Weisbach V, Hansmann L, Lammoglia-Cobo F, Remberger M, Stelljes M, Ayuk F, Zeiser R, Mackensen A. Gerbitz A, et al. Front Immunol. 2023 Oct 30;14:1251593. doi: 10.3389/fimmu.2023.1251593. eCollection 2023. Front Immunol. 2023. PMID: 37965339 Free PMC article. Clinical Trial. - A bivalent CMV vaccine formulated with human compatible TLR9 agonist CpG1018 elicits potent cellular and humoral immunity in HLA expressing mice.
Dasari V, Beckett K, Horsefield S, Ambalathingal G, Khanna R. Dasari V, et al. PLoS Pathog. 2022 Jun 23;18(6):e1010403. doi: 10.1371/journal.ppat.1010403. eCollection 2022 Jun. PLoS Pathog. 2022. PMID: 35737741 Free PMC article. - Battle between Host Immune Cellular Responses and HCMV Immune Evasion.
Manandhar T, Hò GT, Pump WC, Blasczyk R, Bade-Doeding C. Manandhar T, et al. Int J Mol Sci. 2019 Jul 24;20(15):3626. doi: 10.3390/ijms20153626. Int J Mol Sci. 2019. PMID: 31344940 Free PMC article. Review. - Clinical-grade generation of peptide-stimulated CMV/EBV-specific T cells from G-CSF mobilized stem cell grafts.
Gary R, Aigner M, Moi S, Schaffer S, Gottmann A, Maas S, Zimmermann R, Zingsem J, Strobel J, Mackensen A, Mautner J, Moosmann A, Gerbitz A. Gary R, et al. J Transl Med. 2018 May 9;16(1):124. doi: 10.1186/s12967-018-1498-3. J Transl Med. 2018. PMID: 29743075 Free PMC article. - Immunodominant cytomegalovirus-specific CD8+ T-cell responses in sub-Saharan African populations.
Malik A, Adland E, Laker L, Kløverpris H, Fardoos R, Roider J, Severinsen MC, Chen F, Riddell L, Edwards A, Buus S, Jooste P, Matthews PC, Goulder PJR. Malik A, et al. PLoS One. 2017 Dec 12;12(12):e0189612. doi: 10.1371/journal.pone.0189612. eCollection 2017. PLoS One. 2017. PMID: 29232408 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
- CA-18029/CA/NCI NIH HHS/United States
- CA-90537/CA/NCI NIH HHS/United States
- U01 AI026503-090003/AI/NIAID NIH HHS/United States
- R01 AI019335-19/AI/NIAID NIH HHS/United States
- R01 CA033084-25A1/CA/NCI NIH HHS/United States
- P01 CA018029-320048/CA/NCI NIH HHS/United States
- AI-19335/AI/NIAID NIH HHS/United States
- HHMI/Howard Hughes Medical Institute/United States
LinkOut - more resources
Other Literature Sources
Molecular Biology Databases
Research Materials